Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-652-8 | CAS number: 67-43-6
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Published data, methods and results sufficiently reported to make a judgement.
Data source
Reference
- Reference Type:
- publication
- Title:
- 1976 Hanford Americanum exposure incident: urinary excretion of trace metals during DTPA treatment
- Author:
- Kalkwarf DR, Thomas VW Jr, Nielson KK, Mauch ML
- Year:
- 1 983
- Bibliographic source:
- Health Phys 45(4): 937-947
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- basic toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- no
Test material
- Reference substance name:
- Calcium trisodium pentetate
- EC Number:
- 235-169-1
- EC Name:
- Calcium trisodium pentetate
- Cas Number:
- 12111-24-9
- Molecular formula:
- C14H18CaN3O10.3Na
- IUPAC Name:
- trisodium 5,8-bis(carboxylatomethyl)-3,13,16-trioxo-2$I3,14$I3,15$I3-trioxa-5,8$I2,11-triaza-1-calcapentacyclo[9.3.3.01.5.01.8.0.1.11]heptadecane-1,1-bis(ylium)-2,14,15-triide
- Reference substance name:
- Ca-DTPA
- IUPAC Name:
- Ca-DTPA
- Details on test material:
- Na3(Ca-DTPA)
Constituent 1
Constituent 2
Method
- Subjects:
- 1 subject exposed to 241 Americanum treated intravenously for three years with DTPA salts (calcium or zinc) to promote the excretion of the 241 Americanum.
- Route of exposure:
- other: intravenous
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
Results and discussion
Any other information on results incl. tables
Administration of Ca-DTPA consistently caused an increased excetion of Zinc in the urine. No other metals appeared to be significantly affected. Administration of ZnDTPA did not produce the same results (after controlling for the Zinc administered with the DTPA).
1g of Ca-DTPA appeared to be associated with an increased zinc excretion of approximately 18 mg.
Applicant's summary and conclusion
- Conclusions:
- Administration of Ca-DTPA caused the increased excretion of zinc in a patient exposed to 241Am. Supplementation with zinc or replacement with Zn_DTPA
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
